Clinical trial NCT01767792: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Official title: Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neurofibromatosis Type 2
Progressive Vestibular Schwannomas
Keywords: Neurofibromatosis Type 2
Progressive Vestibular Schwannomas
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2013-01-14
Enrollment: 22
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the hearing response rate at 24 weeks after treatment with bevacizumab for symptomatic vestibular schwannomas (VS) in children and young adults with Neurofibromatosis Type 2 (NF 2).

Detailed description: Subjects will be treated with open-label bevacizumab 10 mg/kg every 2 weeks for 24 weeks (induction therapy). Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 or 24 will be taken off of protocol. At week 24, patients with a clinical response or stable disease (together comprising "clinical benefit") will transition to maintenance therapy with bevacizumab. During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance).

Subjects will be allowed to increase their bevacizumab dose to 10 mg/kg every 2 weeks during maintenance therapy if they experience hearing decline during maintenance therapy (defined as decrease in word recognition score below the 95% critical difference compared with the word recognition score at baseline, Appendix A). Subjects will be taken off of study if their word recognition score does not remain within the 95% critical difference after receiving bevacizumab 10 mg/kg every 2 weeks.

Eligibility criteria: Inclusion Criteria - Participants must meet the following criteria on screening examination to be eligible to participate in the study:

* Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National Institute of Health (NIH) criteria or Manchester criteria, or by detection of a causative mutation in the Neurofibromatosis 2 (NF2) gene.
* Patients must have measurable disease, defined as at least one VS \> 1.0 ml (on volumetric analysis) that can be accurately measured by contrast-enhanced cranial MRI scan with fine cuts through the internal auditory canal (3 mm slices, no skip).
* Age 6 years or greater (no upper limit) on day 1 of treatment. Given the potential risk of long-term bevacizumab use, children under age 6 are not eligible for treatment. No upper limit for adults.
* Life expectancy of greater than 1 year.
* Karnofsky performance status ≥ 70.
* Participants must have normal organ and marrow function as defined below with definitions micro liter (mcL), Aspartate aminotransferase (AST), Serum glutamic oxaloacetic transaminase (SGOT), Alanine aminotransferase (ALT), Serum glutamic pyruvic transaminase (SGPT):
* Leukocytes \> 3,000/mcL
* Absolute neutrophil count \> 1,500/mcL
* Platelets \> 100,000/mcL
* Total bilirubin within normal institutional limits
* AST (SGOT)/ALT (SGPT) \< 2.5 X institutional upper limit of normal
* Patients must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥60ml/min/1.73 m2 or a normal serum creatinine based on age described in the table below:
* Age Maximum Serum Creatinine (mg/dL) 6 to \< 10 years 1(Male) 1(Female) 10 to \< 13 years 1.2(Male) 1.2(Female) 13 to \< 16 years 1.5(Male) 1.4(Female

  ≥ 16 years 1.7(Male) 1.4(Female)
* Subjects must have a target VS with the following qualities:
* Not amenable to surgery due to patient refusal, high risk for surgical complications (e.g., damage to lower cranial nerve function, tumor size \> 3 cm in longest diameter, or multilobulated tumor appearance on MRI scan).
* Associated with a word recognition score of \< 85%
* Documented clinical progression defined as EITHER:
* Progressive hearing loss (defined as a decline in word recognition score below the 95% critical difference interval from baseline score \[Appendix A\] related to VS (i.e., not due to prior interventions such as surgery or radiation)

OR

* Progressive tumor growth in the preceding 18 months, defined as ≥ 20% increase in volume
* The effects of bevacizumab on the developing human fetus are unknown. For this reason and because bevacizumab agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Ability to understand and the willingness to sign written informed consent and assent documents.
* Must have established relationship with primary care physician and provide contact information

Exclusion Criteria:

* Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
* Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Prior radiation treatment to the target vestibular schwannoma is allowed if provided 3 years prior to participation in the clinical trial. Prior radiation treatment to non-target tumors is allowed.
* Participants may not be receiving any other study agents.
* Patients with nervous system tumors associated with NF2 (e.g., schwannomas, meningiomas, ependymomas, or gliomas) will not be excluded from this clinical trial unless (in the opinion of the investigator) these tumors are growing and are likely to require treatment during the clinical trial.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab.
* Patients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to bevacizumab.
* Inability to tolerate periodic MRI scans or gadolinium contrast.
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
* History of arterial/myocardial disease.
* Clinically significant cardiovascular disease, such as:
* Inadequately controlled hypertension (HTN) (for adults: Systolic Blood Pressure (SBP) \> 160 mmHg and/or Diastolic Blood Pressure (DBP) \> 90 mmHg despite antihypertensive medication; for children: please refer to Appendix D for age-appropriate values indicating ≥ Grade 2)
* History of cerebrovascular accident (CVA) within 12 months
* Myocardial infarction or unstable angina within 12 months
* New York heart association grade II or greater congestive heart failure
* Serious and inadequately controlled cardiac arrhythmia
* Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection)
* Clinically significant peripheral vascular disease
* Pregnant women are excluded from this study because bevacizumab is an anti-angiogenic agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with bevacizumab, breastfeeding should be discontinued if the mother is treated with bevacizumab. These potential risks may also apply to other agents used in this study.
* HIV-positive patients or cancer survivors are eligible for this study if they fulfill all other eligibility criteria.
* Concurrent use of anti-coagulant drugs (not including prophylactic doses), history of coagulopathy, or evidence of bleeding diathesis or coagulopathy.
* Imaging (CT or MRI) evidence of hemorrhage deemed significant by the treating physician (\> grade 1). Subjects with history of central nervous system (CNS) hemorrhage are not eligible.
* Urine protein should be screened by urine analysis for Urine Protein Creatinine (UPC) ratio. For UPC ratio \> 0.5, 24-hour urine protein should be obtained and the level should be \<1000 mg for patient enrollment.
* Serious or non-healing wound, ulcer or bone fracture.
* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to day 1.
* Invasive procedures defined as follows:
* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy
* Brain biopsy within 28 days prior to day 1 of therapy (wounds must be fully healed from brain biopsies performed more than 28 days prior to day 1 of therapy)
* Anticipation of need for major surgical procedures during the course of the study
* Core biopsy within 7 days prior to D1 therapy
* Prior treatment with bevacizumab.

Primary outcomes:
measure: Improvement in Hearing
timeFrame: 6 months
Secondary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: 6 months
measure: Tolerability of Bevacizumab During Induction (High Dose) Therapy
timeFrame: 6 months
measure: Durability of Hearing Response During Maintenance (Low Dose) Therapy
timeFrame: 2 years
measure: Changes in Pure Tone Average (PTA) on Audiology Compared With Baseline, Measured in Decibels (dBHL).
timeFrame: Weeks 25, 49, 73, 98
measure: Changes in Distress Related to Tinnitus During Induction (High Dose) Treatment.
timeFrame: 6 months (induction phase)
measure: Durability of Radiographic Response
timeFrame: 2 years
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Children's Hospital Los Angeles
state: California
city: Washington
country: United States
facility: Children's National Medical Center
state: District of Columbia
city: Atlanta
country: United States
facility: Children's HealthCare of Atlanta
state: Georgia
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Indianapolis
country: United States
facility: Indiana Unversity
state: Indiana
city: Bethesda
country: United States
facility: National Cancer Institute (NCI)
state: Maryland
city: Boston
country: United States
facility: Children' Hospital Boston and Massachusetts General Hospital
state: Massachusetts
city: Saint Louis
country: United States
facility: Washington University - St. Louis
state: Missouri
city: New York
country: United States
facility: New York University Medical Center
state: New York
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
affiliation: Massachusetts General Hospital
name: Scott Plotkin, MD
role: STUDY_CHAIR
References: